Synergistic effects of leflunomide and benazepril in streptozotocin-induced diabetic nephropathy

Nephron - Experimental Nephrology

Volumn 126, Issue 3, 2014, Pages 148-156

  Jin, Hua ^a   Piao, Shang Guo ^a,b   Jin, Ji Zhe ^a   Jin, Ying Shun ^a   Cui, Zhen Hua ^a   Jin, Hai Feng ^a   Zheng, Hai Lan ^a   Li, Jin Ji ^a   Jiang, Yu Ji ^a   Yang, Chul Woo ^b   Li, Can ^a  

^a YANBIAN UNIVERSITY   (China)

^b The Catholic University of Korea   (South Korea)

Author keywords

8 Hydroxy 2' deoxyguanosine; Benazepril; Connective tissue growth factor; Diabetic nephropathy; Leflunomide; Toll like receptor 2

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BENAZEPRIL; CONNECTIVE TISSUE GROWTH FACTOR; LEFLUNOMIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; STREPTOZOCIN; TOLL LIKE RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; GLUCOSE; ANTIFIBRINOLYTIC AGENT; BENZAZEPINE DERIVATIVE; ISOXAZOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET RESTRICTION; DRUG POTENTIATION; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INFLAMMATORY CELL; MALE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; URINARY EXCRETION; ANIMAL TISSUE; COMPARATIVE STUDY; DIABETES CONTROL; DRUG ACTIVITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INVESTIGATIVE PROCEDURES; KIDNEY MASS; RANDOMIZED CONTROLLED TRIAL; UPREGULATION; WEIGHT REDUCTION; WISTAR RAT; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFIBRINOLYTIC AGENTS; BENZAZEPINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG SYNERGISM; ISOXAZOLES; MALE; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84900883818     PISSN: None     EISSN: 16602129     Source Type: Journal    
DOI: 10.1159/000362556     Document Type: Article

References (17)

1. Yu WM, Wang H, Ren XJ, Liu JP, Wang JY: Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin- induced diabetic rats. Nephrology (Carlton) 2012; 17:380-389.
2. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984; 74:1143-1155. (Pubitemid 15210185)
3. Li C, Yang CW, Park CW, Ahn HJ, Kim WY, Yoon KH, Suh SH, Lim SW, Cha JH, Kim YS, Kim J, Chang YS, Bang BK: Long-term treatment with ramipril attenuates renal osteo-pontin expression in diabetic rats. Kidney Int 2003; 63:454-463. (Pubitemid 36126792)
4. Qi XM, Wu GZ, Wu YG, Lin H, Shen JJ, Lin SY: Renoprotective effect of breviscapine through suppression of renal macrophage recruitment in streptozotocin-induced diabetic rats. Nephron Exp Nephrol 2006; 104:e147-e157. (Pubitemid 44885062)
5. Singh VP, Le B, Khode R, Baker KM, Kumar R: Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibro-sis. Diabetes 2008; 57:3297-3306.
6. Crews GM, Erickson L, Pan F, Fisniku O, Jang MS, Wynn C, Benediktsson H, Kobayashi M, Jiang H: Down-regulation of TGF-β and VCAM-1 is associated with successful treatment of chronic rejection in rats. Transplant Proc 2005; 37:1926-1928. (Pubitemid 40790871)
7. Kim DH, Yoo TH, Kang HY, Nam BY, Kwak SJ, Kim JK, Park JT, Han SH, Kang SW: Gam-ma-linolenic acid exerts anti-inflammatory and anti-fibrotic effects in diabetic nephropa-thy. Yonsei Med J 2012; 53:1165-1175.
8. Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G, Gambino R, Vergola D, Pinach S, Perin PC, Camussi G, Gruden G: Effect of the monocyte chemoattractant pro-tein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009; 58:2109-2118.
9. Mudaliar H, Pollock C, Komala MG, Chad-ban S, Wu H, Panchapakesan U: The role of Toll-like receptor proteins (TLR)-2 and-4 in mediating inflammation in proximal tubules. Am J Physiol Renal Physiol 2013; 305:F143-F154.
10. Cutolo M, Capellino S, Montagna P, Sulli A, Seriolo B, Villaggio B: Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients. Ann Rheum Dis 2006; 65: 728-735. (Pubitemid 43799170)
11. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Far-nell J, Rosenburg R, Veale DJ, Breedveld FC, Emery P, Tak PP: Modulation of inflammation and metalloproteinase expression in sy-novial tissue by leflunomide and methotrex-ate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43:1820-1830.
12. 1 and connective tissue growth factor in strep-tozotocin-induced diabetic rats. Ren Fail 2012; 34:83-87.
13. Chiu J, Khan ZA, Farhangkhoee H, Chakra-barti S: Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-κB. Nutrition 2009; 25:964-972.
14. Choi R, Kim BH, Naowaboot J, Lee MY, Hyun MR, Cho EJ, Lee ES, Lee EY, Yang YC, Chung CH: Effects of ferulic acid on diabetic ne-phropathy in a rat model of type 2 diabetes. Exp Mol Med 2011; 43:676-683.
15. 1 by activating the Nrf2/ARE pathway in glomerular mesangial cells. Free Radic Biol Med 2013; 65: 528-540.
16. Karaman A, Turkmen E, Gursul C, Tas E, Fadillioglu E: Prevention of renal ischemia/reperfusion-induced injury in rats by lefluno-mide. Int J Urol 2006; 13:1434-1441. (Pubitemid 44657055)
17. Stosic-Grujicic S, Dimitrijevic M, Bartlett R: Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insu-litis and diabetes. Clin Exp Immunol 1999; 117:44-50. (Pubitemid 29292776)